Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$131.95 -1.2%	$133.54	$99.71 ▼ $141.23	$229.56B	0.73	6.15 million shs	4.66 million shs
AMGN Amgen	$295.27 -1.7%	$283.28	$253.30 ▼ $346.85	$158.77B	0.49	2.84 million shs	1.61 million shs
GILD Gilead Sciences	$109.64 -4.3%	$107.62	$68.14 ▼ $119.96	$136.38B	0.29	7.70 million shs	6.11 million shs
PFE Pfizer	$25.65 -0.5%	$23.86	$20.92 ▼ $31.54	$145.83B	0.58	41.82 million shs	31.68 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.17%	-0.04%	-0.30%	+5.36%	+29.73%
AMGN Amgen	+1.30%	+0.71%	+2.37%	+5.03%	-6.62%
GILD Gilead Sciences	+1.15%	+2.93%	+4.04%	+10.53%	+66.60%
PFE Pfizer	+0.81%	+1.27%	+6.06%	+17.72%	-9.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.918 of 5 stars	2.4	3.0	4.2	4.5	3.3	2.5	2.5
AMGN Amgen	4.3874 of 5 stars	2.2	2.0	3.3	3.9	4.1	2.5	0.6
GILD Gilead Sciences	4.8429 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
PFE Pfizer	4.9782 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$143.11	8.46% Upside
AMGN Amgen	2.35	Hold	$307.82	4.25% Upside
GILD Gilead Sciences	2.77	Moderate Buy	$111.38	1.59% Upside
PFE Pfizer	2.45	Hold	$28.55	11.31% Upside

Current Analyst Ratings Breakdown

Latest AMGN, GILD, PFE, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ABT Abbott Laboratories	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$140.00 ➝ $145.00
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$42.34B	5.42	$6.52 per share	20.24	$27.62 per share	4.78
AMGN Amgen	$33.42B	4.75	$30.25 per share	9.76	$10.93 per share	27.01
GILD Gilead Sciences	$28.75B	4.74	$6.65 per share	16.48	$15.44 per share	7.10
PFE Pfizer	$62.46B	2.33	$4.38 per share	5.86	$15.62 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.11	23.03	2.53	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
AMGN Amgen	$4.09B	$10.96	26.94	13.80	2.68	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.08	13.52	0.73	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.59	8.47	0.93	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest AMGN, GILD, PFE, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	AMGN Amgen	$5.21	N/A	N/A	N/A	$8.86 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.79%	N/A	30.61%	54 Years
AMGN Amgen	$9.52	3.22%	N/A	86.86%	14 Years
GILD Gilead Sciences	$3.16	2.88%	N/A	66.53%	10 Years
PFE Pfizer	$1.72	6.71%	N/A	124.64%	16 Years

Latest AMGN, GILD, PFE, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
AMGN Amgen	8.70	1.17	0.88
GILD Gilead Sciences	1.16	1.37	1.23
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AMGN Amgen	0.76%
GILD Gilead Sciences	0.27%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

AMGN, GILD, PFE, and ABT Headlines

Recent News About These Companies

“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now

5 hours ago | 247wallst.com

Pfizer (NYSE:PFE) Stock Price Down 1.3% - Here's Why

5 hours ago | marketbeat.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

5 hours ago | zacks.com

Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis

5 hours ago | theglobeandmail.com

Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema

5 hours ago | tipranks.com

Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Potential Game-Changer

5 hours ago | tipranks.com

Pfizer’s Promising Migraine Study in Adolescents: What Investors Should Know

5 hours ago | tipranks.com

Pfizer’s Latest Study on HER2-positive Breast Cancer Treatment: Key Insights for Investors

5 hours ago | tipranks.com

Pfizer’s Inclacumab Study: A Potential Game-Changer for Sickle Cell Disease

5 hours ago | tipranks.com

Pfizer’s New Study on COVID-19 Vaccine Effectiveness: What Investors Need to Know

5 hours ago | tipranks.com

Pfizer’s New Phase 1 Study: A Potential Game-Changer in Cancer Treatment?

5 hours ago | tipranks.com

Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know

5 hours ago | tipranks.com

Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for Infant RSV Protection

5 hours ago | tipranks.com

Pfizer’s EPIC-Peds Study: New Insights into Pediatric COVID-19 Treatment

July 11 at 12:08 PM | tipranks.com

Pfizer’s Palbociclib Study: Real-World Insights on Advanced Breast Cancer Treatment

July 11 at 12:07 PM | tipranks.com

Pfizer’s Tukysa Study: A Closer Look at Safety and Efficacy in South Korea

July 11 at 12:07 PM | tipranks.com

Pfizer Inc. (NYSE:PFE) Stock Position Lifted by Callahan Advisors LLC

July 11 at 8:40 AM | marketbeat.com

Barry Investment Advisors LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

July 11 at 8:24 AM | marketbeat.com

SteelPeak Wealth LLC Has $5.60 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 11 at 8:23 AM | marketbeat.com

Croban Purchases New Position in Pfizer Inc. (NYSE:PFE)

July 11 at 7:30 AM | marketbeat.com

Bernstein Sticks to Its Hold Rating for Pfizer (PFE)

July 10 at 10:50 PM | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

AMGN, GILD, PFE, and ABT Company Descriptions

Abbott Laboratories NYSE:ABT

$131.94 -1.66 (-1.24%)

Closing price 03:58 PM Eastern

Extended Trading

$131.89 -0.06 (-0.04%)

As of 05:35 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$295.27 -5.10 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$295.25 -0.02 (-0.01%)

As of 05:37 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$109.64 -4.90 (-4.28%)

Closing price 04:00 PM Eastern

Extended Trading

$109.64 0.00 (0.00%)

As of 05:36 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Pfizer NYSE:PFE

$25.65 -0.13 (-0.50%)

Closing price 03:59 PM Eastern

Extended Trading

$25.64 0.00 (-0.02%)

As of 05:40 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time